Андрианов А. М., Кашин И. А., Николаев Г. И., Тузиков А. В. IN SILICO ДИЗАЙН И ОЦЕНКА ПОТЕНЦИАЛЬНОЙ АКТИВНОСТИ НОВЫХ ИНГИБИТОРОВ ВИЧ-1 − МИМЕТИКОВ ПЕРВИЧНОГО РЕЦЕПТОРА CD4 БЕЛКА GP120 ОБОЛОЧКИ ВИРУСА. Доклады Национальной академии наук Беларуси. 2017;61(3):47-57.
1. Андрианов, А. М. Конформационный анализ белков. Теория и приложения / А. М. Андрианов. – Минск: Белорусская наука, 2013. – 518 с.
2. Kolb, H. C. Click chemistry: Diverse chemical function from a few good reactions / H. C. Kolb, M. G. Finn, K. B. Sharpless // Angew. Chem. Int. Ed. – 2001. – Vol. 40, N 11. – P. 2004–2021. doi.org/10.1002/1521-3773(20010601)40:11%3C2004::aid-anie2004%3E3.3.co;2-x
3. Arts, E. J. HIV-1 antiretroviral drug therapy / E. J. Arts, D. J. Hazuda // Cold Spring Harb. Perspect. Med. – 2012. – Vol. 2, N 4. – a007161. doi: 10.1101/cshperspect.a007161
4. Tilton, J. C. Entry inhibitors in the treatment of HIV-1 infection / J. C. Tilton, R. W. Doms // Antiviral Res. – 2010. – Vol. 85, N 1. – P. 91–100. doi.org/10.1016/j.antiviral.2009.07.022
5. Andrianov, A. M. HIV-1 gp120 V3 loop for anti-AIDS drug discovery: computer-aided approaches to the problem solving / A. M. Andrianov // Expert Opin. Drug Discov. – 2011. – Vol. 6, N 4. – P. 419–435. doi: 10.1517/17460441.2011.560603
6. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody / P. D. Kwong [et al.] // Nature. – 1998. – Vol. 393. – P. 648–659. doi:10.1038/31405
7. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings / C. A. Lipinski [et al.] // Adv. Drug Deliv. Rev. – 2001. – Vol. 46, N 1–3. – P. 3–26. dx.doi.org/10.1016/S0169-409X(00)00129-0
8. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: Conversion of a viral entry agonist to an antagonist / J. R. Courter [et al.] // Acc. Chem. Res. – 2014. – Vol. 47, N 4. – P. 1228–1237. doi. org/10.1021/ar4002735
9. Structure-based design of a small molecule CD4-antagonist with broad spectrum anti-HIV-1 activity / F. Curreli [et al.] // J. Med. Chem. – 2015. – Vol. 58, N 17. – P. 6909–6927. doi.org/10.1021/acs.jmedchem.5b00709
10. Liu, Y. Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis / Y. Liu, A. Schön, E. Freire // Chem. Biol. Drug Des. – 2013. – Vol. 81, N 1. – P. 72–78. doi.org/10.1111/cbdd.12075
11. The human immunodeficiency virus-gp120 binding-site on CD4 − Delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic-structure / U. Moebius [et al.] // J. Exp. Med. – 1992. – Vol. 176, N 2. – P. 507–517. doi.org/10.1084/jem.176.2.507
12. Identification of individual human-immunodeficiency-virus type-1 gp120 amino-acids important for CD4 receptor-binding / U. Olshevsky [et al.] // J. Virol. – 1990. – Vol. 64, N 12. – P. 5701–5707.
13. Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4 / Q. Zhao [et al.] // Virology. – 2005. – Vol. 339, N 2. – P. 213–225. doi.org/10.1016/j. virol.2005.06.008
14. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops / Y. D. Kwon [et al.] // Proc. Natl. Acad. Sci. USA. – 2012. – Vol. 109, N 15. – P. 5663–5668. doi.org/10.1073/pnas.1112391109
15. Durrant, J. D. AutoGrow: a novel algorithm for protein inhibitor design / J. D. Durrant, R. E. Amaro, J. A. McCammon // Chem. Biol. Drug Des. – 2009. – Vol. 73, N 2. – P. 168–178. doi.org/10.1111/j.1747-0285.2008.00761.x
